

<b>Clinical Policy Title:</b>	tovorafenib
<b>Policy Number:</b>	RxA.850
<b>Drug(s) Applied:</b>	Ojemda
<b>Original Policy Date:</b>	12/16/2024
<b>Last Review Date:</b>	12/11/2025
<b>Line of Business Policy Applies to:</b>	All lines of business (except Medicare)

## Criteria

### I. Initial Approval Criteria

#### A. Pediatric low-grade glioma (must meet all):

1. Diagnosis of relapsed or refractory pediatric low-grade glioma;
2. Disease is positive for one of the following (a, b, or c):
  - a. BRAF fusion;
  - b. BRAF rearrangement;
  - c. BRAF V600 mutation.

#### Approval Duration

**All Lines of Business (except Medicare):** 12 months

### II. Continued Therapy Approval

#### A. Pediatric low-grade glioma (must meet all):

1. Member is currently receiving medication in the past 120 days.

#### Approval Duration

**All Lines of Business (except Medicare):** 12 months

## References

1. Ojemda. Package Insert. Day One Biopharmaceuticals; 2024. Available at: <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad&type=display>. Accessed December 16, 2024.

Review/Revision History	Review/Revision Date	P&T Approval Date
Policy established.	12/16/2024	12/05/2024
Policy reviewed.	12/11/2025	12/11/2025

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.